Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
Pharmalittle: We’re reading about Zepbound price and dose changes, compounders suing FDA, and more
Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback